Poor Reporting of Scientific Leadership Information in Clinical Trial Registers
Author Information
Author(s): Melanie Sekeres, Jennifer L. Gold, An-Wen Chan, Joel Lexchin, David Moher, Marleen L. P. Van Laethem, James Maskalyk, Lorraine Ferris, Nathan Taback, Paula A. Rochon
Primary Institution: Kunin-Lunenfeld Applied Research Unit, Baycrest, Toronto, Ontario, Canada
Hypothesis
What proportion of registered clinical trials provide valid scientific leadership information?
Conclusion
Many clinical trials fail to provide required scientific leadership and contact information, undermining accountability.
Supporting Evidence
- 74% of trial entries listed the name of the study chair or principal investigator.
- 51% of non-industry funded trials provided e-mail contact information.
- Industry funded trials were less likely to provide scientific leadership information.
Takeaway
The study found that many clinical trials don't list who is in charge or how to contact them, which is important for trust.
Methodology
The study reviewed clinical trial entries from ISRCTN and ClinicalTrials.gov to assess compliance with registration requirements.
Potential Biases
The sample may not reflect the broader issues in clinical trial registration due to its focus on Canadian trials.
Limitations
The study focused only on trials with Canadian investigators, which may not represent global compliance.
Participant Demographics
The study included clinical trials with Canadian investigators.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 95–701
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website